Analysts’ Viewpoint on Vaginitis Diagnostics Market Scenario
Screening and detection of bacterial, yeast, fungi, and viral samples in clinical pathology using microscopy and vaginal testing panels have led to less turnaround time. This is ascribed to lower chances of producing false positive results using these panels because of their broad coverage of microbes of different classes, sensitivity, and effectiveness for the production of results. The number of diagnostic vaginal testing procedures is likely to increase as more women undergoing vaginal test are likely to benefit from this advancement, which in turn is expected to propel the global market during the forecast period. Incidence of vaginal disorders is common among young women, and around 32% of the female population struggles with different kinds of vaginal complications. Most vaginal infections are asymptomatic and hence, it is difficult to predict the initial onset. Therefore, high specificity of the nucleic acid amplification test presents significant opportunities for leading players in the global market.
Vaginitis is defined as any condition with symptoms of abnormal vaginal discharge, odor, and irritation, itching, or burning. Bacterial vaginosis is the most common cause of vaginal symptoms among women. According to the CDC, in 2021, prevalence of vaginitis in the U.S. is estimated to be 21.2 million (29.2%) among women aged 14 to 49. Vaginitis diagnostic test is used for the detection of diseases such as bacteria associated with bacterial vaginosis, candida species associated with vulvovaginal candidiasis, and trichomonas vaginosis. Vaginosis diagnosis and vulvovaginal candidiasis vaginitis diagnosis (VVC diagnosis) are performed using a combination of clinical signs and symptoms with potassium hydroxide microscopy culture that can be helpful for the diagnosis of bacterial vaginitis. Real-time polymerase chain reaction (PCR) and amplification of specific DNA targets are the technologically advanced tests available in the global market for the purpose of fast vaginosis diagnosis.
The COVID-19 pandemic had a negative effect on the global vaginitis diagnostics market. Governments of affected countries postponed non-essential treatment and patient visits during the breakout year of COVID-19. Hospital personnel and medical staff were moved to COVID-19 cases, prompting the suspension of outpatient visits for sexual diseases. This led to a substantial decline in overall vaginosis diagnosis and VVC diagnosis & treatments, which in turn hampered the vaginitis diagnostic market. Key players reported lower revenue due to the pandemic, which led to a decline in Y-o-Y global vaginitis diagnostics market share. However, the market has recovered from COVID-19 due to the easing of restrictions by governments across the globe.
In terms of testing type, the nucleic acid amplification test segment held major market share in 2021. Increase in the usage of molecular nucleic acid amplification tests for vaginosis diagnosis & VVC diagnosis and screening of vaginal infections due to high accuracy and sensitivity in the production of results is anticipated to propel the segment in the near future. Nucleic acid amplification tests (NAATs), such as PCR, can identify as little as one organism in a sample. These employ techniques that multiply a nucleic acid sequence enzymatically, resulting in the synthesis of billions of copies in a short time.
Based on disease type, the bacterial vaginosis/vaginitis segment dominated the global market in 2021. Bacterial vaginosis (BV) is the most prevalent cause of vaginal discharge in women of reproductive age. It is not a sexually transmitted disease; however, sexual activity is a risk factor for its transmission. It is linked to changes in vaginal ecology, including a reduction in the vaginal lactobacilli population and an overgrowth of anaerobes and G. vaginalis. Bacterial vaginosis is the more prevalent vaginal microbiota among women of reproductive age. This has increased the demand for bacterial vaginosis diagnosis. For instance, the prevalence of bacterial vaginosis in North America stands at around 20% to 30%.
In terms of end-user, the hospitals segment accounted for major share of the global market in 2021. Increase in focus on providing quality care, rise in emphasis on early diagnostics of vaginal infections, and surge in the number of well-equipped specialty hospitals are expected to augment the hospitals segment during the forecast period. Growth of the segment can be ascribed to rise in prevalence of infectious diseases such as vaginal infections and increase in awareness about these infections among people.
North America accounted for the largest share of the global market in 2021. The region is projected to be a highly attractive market during the forecast period. Increase in health awareness, rise in investment in healthcare infrastructure, and surge in demand for better healthcare facilities propel the vaginitis diagnostics market in North America. The U.S. dominated the market in North America in 2021. The trend is anticipated to continue during the forecast period due to large number of patients and favorable reimbursement for vaginitis. Europe was the second-largest market for vaginitis diagnostics in 2021. Favorable regulatory scenario, approval of products, and presence of highly developed infrastructure are likely to augment the vaginitis diagnostics market size in the region in the next few years.
As per global vaginitis diagnostics market forecast, the market in Asia Pacific is projected to grow at a rapid pace during the forecast period owing to increase in the geriatric population in countries such as Japan and China, higher incidence rate of vaginitis, rise in per capita income, and improved healthcare infrastructure. Moreover, increase in healthcare expenditure and investments by key players in emerging economies is expected to propel the market in the region.
The vaginitis diagnostics market report includes vital information about the key players operating in the global market. Companies focus on strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market. Thermo Fisher Scientific, Laboratory Corporation of America Holdings, Cepheid (Danaher Corporation), Abbott Laboratories, QIAGEN, F. Hoffmann-La Roche Ltd., Hologic, Quidel Corporation, Quest Diagnostics Incorporated, Atrida, and Becton, Dickinson and Company are the prominent players operating in the global market.
Key players have been profiled in the vaginitis diagnostics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 1.7 Bn |
|
Market Forecast Value in 2031 |
More than US$ 4.1 Bn |
|
Compound Annual Growth Rate (CAGR) |
9.5% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global vaginitis diagnostics market was valued at US$ 1.7 Bn in 2021.
The global vaginitis diagnostics market is projected to reach more than US$ 4.1 Bn by 2031.
The global vaginitis diagnostics market is anticipated to advance at a CAGR of 9.5% from 2022 to 2031.
Increase in the incidence & prevalence of vaginal infection and rise in research & development on novel techniques.
North America is expected to account for major share of the global vaginitis diagnostics market during the forecast period.
Laboratory Corporation of America Holdings, Cepheid (Danaher Corporation), Abbott Laboratories, QIAGEN, F. Hoffmann-La Roche Ltd., Hologic, Quidel Corporation, Quest Diagnostics Incorporated, Atrida, and Becton, Dickinson and Company.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vaginitis Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Testing Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Vaginitis Diagnostics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Industry Events (New Product Launches/Key Mergers & Acquisitions)
5.2. Technological Advancements
5.3. Disease Incidence and Prevalence
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/ Mid-/ Long-Term Impact)
6. Global Vaginitis Diagnostics Market Analysis and Forecast, by Testing Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Testing Type, 2017–2031
6.3.1. Nucleic Acid Amplification Assays
6.3.2. DNA Probe
6.3.3. Clinical Test
6.4. Market Attractiveness Analysis, by Testing Type
7. Global Vaginitis Diagnostics Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease Type, 2017–2031
7.3.1. Bacterial Vaginosis/Vaginitis
7.3.2. Vulvovaginal Candidiasis
7.3.3. Trichomoniasis
7.3.4. Others
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Vaginitis Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Specialty Clinics
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Vaginitis Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Vaginitis Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Testing Type, 2017–2031
10.2.1. Nucleic Acid Amplification Assays
10.2.2. DNA Probe
10.2.3. Clinical Test
10.3. Market Value Forecast, by Disease Type, 2017–2031
10.3.1. Bacterial Vaginosis/Vaginitis
10.3.2. Vulvovaginal Candidiasis
10.3.3. Trichomoniasis
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Testing Type
10.6.2. By Disease Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Vaginitis Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Testing Type, 2017–2031
11.2.1. Nucleic Acid Amplification Assays
11.2.2. DNA Probe
11.2.3. Clinical Test
11.3. Market Value Forecast, by Disease Type, 2017–2031
11.3.1. Bacterial Vaginosis/Vaginitis
11.3.2. Vulvovaginal Candidiasis
11.3.3. Trichomoniasis
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Testing Type
11.6.2. By Disease Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Vaginitis Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Testing Type, 2017–2031
12.2.1. Nucleic Acid Amplification Assays
12.2.2. DNA Probe
12.2.3. Clinical Test
12.3. Market Value Forecast, by Disease Type, 2017–2031
12.3.1. Bacterial Vaginosis/Vaginitis
12.3.2. Vulvovaginal Candidiasis
12.3.3. Trichomoniasis
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Testing Type
12.6.2. By Disease Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Vaginitis Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Testing Type, 2017–2031
13.2.1. Nucleic Acid Amplification Assays
13.2.2. DNA Probe
13.2.3. Clinical Test
13.3. Market Value Forecast, by Disease Type, 2017–2031
13.3.1. Bacterial Vaginosis/Vaginitis
13.3.2. Vulvovaginal Candidiasis
13.3.3. Trichomoniasis
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Testing Type
13.6.2. By Disease Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Vaginitis Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Testing Type, 2017–2031
14.2.1. Nucleic Acid Amplification Assays
14.2.2. DNA Probe
14.2.3. Clinical Test
14.3. Market Value Forecast, by Disease Type, 2017–2031
14.3.1. Bacterial Vaginosis/Vaginitis
14.3.2. Vulvovaginal Candidiasis
14.3.3. Trichomoniasis
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Specialty Clinics
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Testing Type
14.6.2. By Disease Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Laboratory Corporation of America Holdings
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Company Financial
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Cepheid (Danaher Corporation)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Company Financial
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Abbott Laboratories
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Company Financial
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. QIAGEN
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Company Financial
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. F. Hoffmann-La Roche Ltd.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Company Financial
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Hologic, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Company Financial
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Quidel Corporation
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Company Financial
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Quest Diagnostics Incorporated
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Company Financial
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Atrida
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Becton, Dickinson and Company
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Company Financial
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Vaginitis Diagnostics Market Value Share, by Testing Type, 2021
Table 02: Global Vaginitis Diagnostics Market Value Share, by Disease Type & End-user, 2021
Table 03: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Testing Type, 2018–2031
Table 04: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2018–2031
Table 05: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031
Table 06: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Region, 2018–2031
Table 07: North America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Testing Type, 2018–2031
Table 08: North America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2018–2031
Table 09: North America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031
Table 10: North America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Country, 2018–2031
Table 11: Europe Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Testing Type, 2018–2031
Table 12: Europe Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2018–2031
Table 13: Europe Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031
Table 14: Europe Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2031
Table 15: Asia Pacific Vaginitis Diagnostics Market (US$ Mn) Forecast, by Testing Type, 2018–2031
Table 16: Asia Pacific Vaginitis Diagnostics Market (US$ Mn) Forecast, by Disease Type, 2018–2031
Table 17: Asia Pacific Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031
Table 18: Asia Pacific Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2031
Table 19: Latin America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2018–2031
Table 20: Latin America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Testing Type, 2018–2031
Table 21: Latin America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031
Table 22: Latin America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2031
Table 23: Middle East & Africa Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2018–2031
Table 24: Middle East & Africa Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Testing Type, 2018–2031
Table 25: Middle East & Africa Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031
Table 26: Middle East & Africa Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2031
List of Figures
Figure 01: Global Vaginitis Diagnostics Market Snapshot
Figure 02: Global Vaginitis Diagnostics Market Segments with Leading Market Share (%), 2021
Figure 03: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast, 2022–2031
Figure 04: Market Value Share (%), by Testing Type, 2021
Figure 05: Market Value Share (%), by Disease Type, 2021
Figure 06: Market Value Share (%), by End-user, 2021
Figure 07: Market Value Share (%), by Region, 2021
Figure 08: Global Vaginitis Diagnostics Market Value Share Analysis, by Testing Type, 2021 and 2031
Figure 09: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Nucleic Acid Amplification Assays, 2018–2031
Figure 10: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by DNA Probe, 2018–2031
Figure 11: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Clinical Test, 2018–2031
Figure 12: Global Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031
Figure 13: Global Vaginitis Diagnostics Market Value Share Analysis, by Disease Type, 2021 and 2031
Figure 14: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Vulvovaginal Candidiasis, 2021-2031
Figure 15: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bacterial Vaginosis/Vaginitis, 2021-2031
Figure 16: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Trichomoniasis, 2021-2031
Figure 17: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2021-2031
Figure 18: Global Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 19: Global Vaginitis Diagnostics Market Value Share (%), by End-user, 2021 and 2031
Figure 20: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals, 2018–2031
Figure 21: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Specialty Clinics, 2018–2031
Figure 22: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Others, 2018–2031
Figure 23: Global Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 24: Global Vaginitis Diagnostics Market Value Share Analysis, by Region, 2021 and 2031
Figure 25: Global Vaginitis Diagnostics Market Attractiveness Analysis, by Region, 2022–2031
Figure 26: North America Vaginitis Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 201–2031
Figure 27: North America Vaginitis Diagnostics Market Value Share (%), by Testing Type, 2021 and 2031
Figure 28: North America Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031
Figure 29: North America Vaginitis Diagnostics Market Value Share (%), by Disease Type, 2021 and 2031
Figure 30: North America Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 31: North America Vaginitis Diagnostics Market Value Share (%), by End-user, 2021 and 2031
Figure 32: North America Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 33: North America Vaginitis Diagnostics Market Value Share (%), by Country, 2021 and 2031
Figure 34: North America Vaginitis Diagnostics Market Attractiveness Analysis, by Country, 2022–2031
Figure 35: Europe Vaginitis Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2031
Figure 36: Europe Vaginitis Diagnostics Market Value Share (%), by Testing Type, 2021 and 2031
Figure 37: Europe Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031
Figure 38: Europe Vaginitis Diagnostics Market Value Share (%), by Disease Type, 2021 and 2031
Figure 39: Europe Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 40: Europe Vaginitis Diagnostics Market Share (%), by End-user, 2021 and 2031
Figure 41: Europe Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 42: Europe Vaginitis Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 43: Europe Vaginitis Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 44: Asia Pacific Vaginitis Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2031
Figure 45: Asia Pacific Vaginitis Diagnostics Market Value Share (%), by Testing Type, 2021 and 2031
Figure 46: Asia Pacific Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031
Figure 47: Asia Pacific Vaginitis Diagnostics Market Value Share (%), by Disease Type, 2021 and 2031
Figure 48: Asia Pacific Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 49: Asia Pacific Vaginitis Diagnostics Market Share (%), by End-user, 2021 and 2031
Figure 50: Asia Pacific Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 51: Asia Pacific Vaginitis Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 52: Asia Pacific Vaginitis Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 53: Latin America Vaginitis Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2031
Figure 54: Latin America Vaginitis Diagnostics Market Value Share (%), by Testing Type, 2021 and 2031
Figure 55: Latin America Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031
Figure 56: Latin America Vaginitis Diagnostics Market Value Share (%), by Disease Type, 2021 and 2031
Figure 57: Latin America Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 58: Latin America Vaginitis Diagnostics Market Share (%), by End-user, 2021 and 2031
Figure 59: Latin America Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 60: Latin America Vaginitis Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 61: Latin America Vaginitis Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 62: Middle East & Africa Vaginitis Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2031
Figure 63: Middle East & Africa Vaginitis Diagnostics Market Value Share (%), by Testing Type, 2021 and 2031
Figure 64: Middle East & Africa Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031
Figure 65: Middle East & Africa Vaginitis Diagnostics Market Value Share (%), by Disease Type, 2021 and 2031
Figure 66: Middle East & Africa Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 67: Middle East & Africa Vaginitis Diagnostics Market Share (%), by End-user, 2021 and 2031
Figure 68: Middle East & Africa Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 69: Middle East & Africa Vaginitis Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 70: Middle East & Africa Vaginitis Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 71: Global Vaginitis Diagnostics Market Share Analysis, by Company (2021)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Vaginitis Diagnostics Market
